Novotech Earns Frost & Sullivan’s 2024 Global Company of the Year
Novotech, a leading biotech Contract Research Organization (CRO), has been named the 2024 Global Company of the Year by Frost & Sullivan. The award recognizes the company’s drive to strengthen clinical development for biotechnology sponsors through practical innovation, seasoned strategic insight, and a broad, on-the-ground global presence.
Why Frost & Sullivan Chose Novotech
The honor spotlights Novotech’s full-service model, designed to accelerate clinical development by pairing advanced analytics with access to diverse patient populations. Unmesh Lal, Global Research Director at Frost & Sullivan, noted that in a fast-changing CRO market, Novotech stands out for its ability to steer through complex regulatory frameworks while understanding the cultural realities that shape trial execution in each region.
Global reach, local know?how
With substantial reach across markets, Novotech delivers tailored solutions that reflect each country’s regulations and cultural context. That local fluency helps speed patient recruitment and raise operational efficiency, which in turn improves the likelihood of successful outcomes for biotechnology clients running time-sensitive trials.
Project management that keeps trials moving
Novotech uses a project manager?centric approach to keep communications clear and decisions timely throughout each study. By emphasizing accountability and consistent coordination from start to finish, the company builds collaborative relationships with sponsors and strengthens its role as a preferred partner in the global CRO landscape.
Technology that lifts every trial
Innovation is another reason behind the award. Novotech continues to invest in state?of?the?art technologies that sharpen day?to?day trial operations. Ongoing work in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud?based platforms supports better data quality, more reliable planning, and greater transparency among all stakeholders—sponsors, investigators, and regulators alike.
Working with industry mainstays
Partnerships with leading platforms such as Veeva and Medidata give Novotech’s clients tools to refine drug development processes. These collaborations help streamline study workflows and reinforce Novotech’s position as a trusted leader in CRO services.
A record that stretches back to 2006
Frost & Sullivan first recognized Novotech as the best CRO in the Asia?Pacific region in 2006, and the company has continued to receive industry accolades in the years since. The 2024 Global Company of the Year Award underscores Novotech’s steady commitment to continuous improvement and to delivering strong results for its partners.
What leadership says
“This award is a tremendous honor for us,” stated Dr. John Moller, CEO of Novotech. “It reflects our team’s hard work and relentless pursuit of innovation and excellence in delivering exceptional outcomes for our clients in biotech and pharmaceuticals. We take pride in leading advancements in clinical development.”
About Novotech
Founded in 1997, Novotech is a global, full?service clinical CRO that partners with biotechnology companies to accelerate the development of new therapeutics at every stage. The company has earned numerous honors for its contributions to the field, including the CRO Leadership Award 2023 and the APAC Company of the Year Award each year since 2006.
Novotech’s comprehensive services include labs, Phase I facilities, regulatory guidance, and expertise built from work on over 5,000 clinical projects—covering Phase I through Phase IV studies as well as bioequivalence research. With 34 locations worldwide and a team of more than 3,000 professionals, Novotech serves as a strategic partner across the clinical trial lifecycle.
Frequently Asked Questions
Why did Frost & Sullivan name Novotech the 2024 Global Company of the Year?
The award recognizes Novotech’s full?service model, innovative use of technology, and consistent execution that helps biotech sponsors advance clinical development efficiently and reliably.
How does Novotech stand out among CROs?
Novotech blends global reach with local expertise, navigating regulatory complexity and cultural nuances to speed recruitment and improve trial efficiency across markets.
Which technologies does Novotech use to improve trials?
The company invests in AI, big data analytics, digital clinical trials, and cloud?based platforms to enhance data quality, streamline planning, and increase transparency for stakeholders.
How long has Novotech been recognized by Frost & Sullivan?
Novotech’s recognition dates back to 2006, when it was named the best CRO in the Asia?Pacific region, with continued accolades culminating in the 2024 Global Company of the Year Award.
What services and experience does Novotech bring to sponsors?
Novotech offers labs, Phase I facilities, regulatory guidance, and experience across more than 5,000 projects spanning Phase I–IV and bioequivalence studies, supported by 34 locations and a team of over 3,000 professionals.
